The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
The diverse functions of the PD1 inhibitory pathway
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Self-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Self-citationGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Self-citationMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Self-citationTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Self-citationT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Transcriptional control of effector and memory CD8+ T cell differentiation
Kaech, S. M., & Cui, W. (2012) · Nature Reviews Immunology · doi:10.1038/nri3307 · Cited by 1,628
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348
Self-citationPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Self-citationTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Self-citationPatsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Self-citationYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Self-citationPotentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Self-citationThe epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection
Paley, M. A., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 902
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Self-citationRoh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Self-citationScharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
Self-citationPersistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice
Murali-Krishna, K., Lau, L. L., Sambhara, S., Lemonnier, F., Altman, J., & Ahmed, R. (1999) · Science · doi:10.1126/science.286.5443.1377 · Cited by 725
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 677
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
Self-citationCasey, K. A., Fraser, K. A., Schenkel, J. M., Moran, A., Abt, M. C., Beura, L. K., Lucas, P. J., Artis, D., Wherry, E. J., Hogquist, K., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200402 · Cited by 639
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639
Self-citationThe integration of T cell migration, differentiation and function
Masopust, D., & Schenkel, J. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3442 · Cited by 627
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
Probst, H. C., McCoy, K., Okazaki, T., Honjo, T., & van den Broek, M. (2005) · Nature Immunology · doi:10.1038/ni1165 · Cited by 554
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Self-citationPatsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Immune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
Antigen-independent memory CD8 T cells do not develop during chronic viral infection
Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N., & Ahmed, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407192101 · Cited by 497
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
Self-citationB7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A., & Wherry, E. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 467
Self-citationThe receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
Sage, P. T., Francisco, L. M., Carman, C. V., & Sharpe, A. H. (2013) · Nature Immunology · doi:10.1038/ni.2496 · Cited by 467
Self-citationA critical role for the programmed death ligand 1 in fetomaternal tolerance
Guleria, I., Khosroshahi, A., Ansari, M. J., Habicht, A., Azuma, M., Yagita, H., Noelle, R. J., Coyle, A., Mellor, A. L., Khoury, S. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050019 · Cited by 439
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 437
A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
Singer, M., Wang, C., Cong, L., Marjanovic, N. D., Kowalczyk, M. S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.052 · Cited by 420
Youngblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
Chamoto, K., Chowdhury, P. S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., & Honjo, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620433114 · Cited by 413
Disparate Individual Fates Compose Robust CD8 + T Cell Immunity
Buchholz, V. R., Flossdorf, M., Hensel, I., Kretschmer, L., Weissbrich, B., Gräf, P., Verschoor, A., Schiemann, M., Höfer, T., & Busch, D. H. (2013) · Science · doi:10.1126/science.1235454 · Cited by 412
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
Heterogeneous Differentiation Patterns of Individual CD8 + T Cells
Gerlach, C., Rohr, J. C., Perié, L., van Rooij, N., van Heijst, J. W. J., Velds, A., Urbanus, J., Naik, S. H., Jacobs, H., Beltman, J. B., et al. (2013) · Science · doi:10.1126/science.1235487 · Cited by 365
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Totpal, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365
Cutting Edge: Gut Microenvironment Promotes Differentiation of a Unique Memory CD8 T Cell Population
Masopust, D., Vezys, V., Wherry, E. J., Barber, D. L., & Ahmed, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2079 · Cited by 357
What does PD-L1 positive or negative mean?
Ribas, A., & Hu-Lieskovan, S. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161462 · Cited by 335
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 330
Self-citationBlazar, B. R., Carreno, B. M., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., Nishimura, H., & Taylor, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1272 · Cited by 329
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
Fife, B. T., Guleria, I., Gubbels Bupp, M., Eagar, T. N., Tang, Q., Bour-Jordan, H., Yagita, H., Azuma, M., Sayegh, M. H., & Bluestone, J. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061577 · Cited by 325
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Self-citationFunctional Responses and Costimulator Dependence of Memory CD4+ T Cells
London, C. A., Lodge, M. P., & Abbas, A. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.265 · Cited by 314
Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection
Scott-Browne, J. P., López-Moyado, I. F., Trifari, S., Wong, V., Chavez, L., Rao, A., & Pereira, R. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.028 · Cited by 313
Exhaustion-associated regulatory regions in CD8 + tumor-infiltrating T cells
Mognol, G. P., Spreafico, R., Wong, V., Scott-Browne, J. P., Togher, S., Hoffmann, A., Hogan, P. G., Rao, A., & Trifari, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620498114 · Cited by 310
Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway
Yu, Y., Tsang, J. C. H., Wang, C., Clare, S., Wang, J., Chen, X., Brandt, C., Kane, L., Campos, L. S., Lu, L., et al. (2016) · Nature · doi:10.1038/nature20105 · Cited by 306
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
Angelosanto, J. M., Blackburn, S. D., Crawford, A., & Wherry, E. J. (2012) · Journal of Virology · doi:10.1128/jvi.00889-12 · Cited by 285
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrié, L., Luescher, I., Speiser, D. E., & Zehn, D. (2013) · Nature Immunology · doi:10.1038/ni.2606 · Cited by 283
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection
Shin, H., Blackburn, S. D., Blattman, J. N., & Wherry, E. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061937 · Cited by 273
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
Targeting T cell metabolism for therapy
O'Sullivan, D., & Pearce, E. L. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.004 · Cited by 254
Hirahara, K., Ghoreschi, K., Yang, X.-P., Takahashi, H., Laurence, A., Vahedi, G., Sciumè, G., Hall, A. O., Dupont, C. D., Francisco, L. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.024 · Cited by 254
Self-citationDuraiswamy, J., Ibegbu, C. C., Masopust, D., Miller, J. D., Araki, K., Doho, G. H., Tata, P., Gupta, S., Zilliox, M. J., Nakaya, H. I., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001783 · Cited by 246
PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues
Keir, M. E., Freeman, G. J., & Sharpe, A. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5064 · Cited by 245
Self-citationProatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice
Gotsman, I., Grabie, N., Dacosta, R., Sukhova, G., Sharpe, A., & Lichtman, A. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31344 · Cited by 239
Self-citationHonda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K. R., Chang, K.-M., Sulkowski, M., Marro, S. O., Anderson, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063818 · Cited by 231
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
Ascierto, M. L., McMiller, T. L., Berger, A. E., Danilova, L., Anders, R. A., Netto, G. J., Xu, H., Pritchard, T. S., Fan, J., Cheadle, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0072 · Cited by 210
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
Frebel, H., Nindl, V., Schuepbach, R. A., Braunschweiler, T., Richter, K., Vogel, J., Wagner, C. A., Loffing-Cueni, D., Kurrer, M., Ludewig, B., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121015 · Cited by 209
PD-1 on dendritic cells impedes innate immunity against bacterial infection
Yao, S., Wang, S., Zhu, Y., Luo, L., Zhu, G., Flies, S., Xu, H., Ruff, W., Broadwater, M., Choi, I.-H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203141 · Cited by 208
Viral acute lower respiratory infections impair CD8+ T cells through PD-1
Erickson, J. J., Gilchuk, P., Hastings, A. K., Tollefson, S. J., Johnson, M., Downing, M. B., Boyd, K. L., Johnson, J. E., Kim, A. S., Joyce, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62860 · Cited by 203
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A., Sayegh, M. H., Blazar, B. R., Freeman, G. J., & Sharpe, A. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003496 · Cited by 202
Self-citationB7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1
Petroff, M. G., Chen, L., Phillips, T. A., Azzola, D., Sedlmayr, P., & Hunt, J. S. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.010058 · Cited by 197
Nishimura, H., Honjo, T., & Minato, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.891 · Cited by 192
Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory
Suresh, M., Whitmire, J. K., Harrington, L. E., Larsen, C. P., Pearson, T. C., Altman, J. D., & Ahmed, R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5565 · Cited by 191
Taylor, A., Harker, J. A., Chanthong, K., Stevenson, P. G., Zuniga, E. I., & Rudd, C. E. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.018 · Cited by 190
Lucas, J. A., Menke, J., Rabacal, W. A., Schoen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 189
Self-citationFuller, M. J., Callendret, B., Zhu, B., Freeman, G. J., Hasselschwert, D. L., Satterfield, W., Sharpe, A. H., Dustin, L. B., Rice, C. M., Grakoui, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312772110 · Cited by 173
Self-citationRescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N., & Greenberg, P. D. (2012) · Science · doi:10.1126/science.1214277 · Cited by 169
A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance
Habicht, A., Dada, S., Jurewicz, M., Fife, B. T., Yagita, H., Azuma, M., Sayegh, M. H., & Guleria, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5211 · Cited by 165
Mueller, S. N., Vanguri, V. K., Ha, S.-J., West, E. E., Keir, M. E., Glickman, J. N., Sharpe, A. H., & Ahmed, R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40040 · Cited by 160
Self-citationKeir, M. E., Latchman, Y. E., Freeman, G. J., & Sharpe, A. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7372 · Cited by 158
Self-citationExpression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Induction and Visualization of Mucosal Memory CD8 T Cells Following Systemic Virus Infection
Kim, S.-K., Schluns, K. S., & Lefrançois, L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4125 · Cited by 146
Yang, J., Riella, L. V., Chock, S., Liu, T., Zhao, X., Yuan, X., Paterson, A. M., Watanabe, T., Vanguri, V. K., Yagita∥, H., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100056 · Cited by 138
Self-citationInterferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Mechanisms of PDL1-mediated regulation of autoimmune diabetes
Guleria, I., Bupp, M. G., Dada, S., Fife, B. T., Tang, Q., Ansari, M. J., Trikudanathan, S., Vadivel, N., Fiorina, P., Yagita∥, H., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.05.013 · Cited by 130
Hirata, S., Senju, S., Matsuyoshi, H., Fukuma, D., Uemura, Y., & Nishimura, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.1888 · Cited by 127
Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade
Reynoso, E. D., Elpek, K. G., Francisco, L. M., Bronson, R. T., Bellemare‐Pelletier, A., Sharpe, A. H., Freeman, G. J., & Turley, S. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802769 · Cited by 126
Self-citationLázár‐Molnár, E., Gácser, A., Freeman, G. J., Almo, S. C., Nathenson, S. G., & Nosanchuk, J. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711918105 · Cited by 125
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 122
RGMs: Structural Insights, Molecular Regulation, and Downstream Signaling
Siebold, C., Yamashita, T., Monnier, P. P., Mueller, B. K., & Pasterkamp, R. J. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.009 · Cited by 118
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111
IL-27 renders DC immunosuppressive by induction of B7-H1
Karakhanova, S., Bedke, T., Enk, A., & Mahnke, K. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1209788 · Cited by 92
Pauken, K. E., Jenkins, M. K., Azuma, M., & Fife, B. T. (2013) · Diabetes · doi:10.2337/db12-1475 · Cited by 89
Self-citationPhares, T. W., Ramakrishna, C., Parra, G. I., Epstein, A. L., Chen, L., Atkinson, R., Stohlman, S. A., & Bergmann, C. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803557 · Cited by 83
Lohmann, T., Leslie, R. D. G., & Londei, M. (1996) · Journal of Autoimmunity · doi:10.1006/jaut.1996.0052 · Cited by 81
Recall Responses by Helpless Memory CD8+ T Cells Are Restricted by the Up-Regulation of PD-1
Fuse, S., Tsai, C.-Y., Molloy, M. J., Allie, S. R., Zhang, W., Yagita∥, H., & Usherwood, E. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802041 · Cited by 75
Molecular biology, genetics and biochemistry of the repulsive guidance molecule family
Severyn, C. J., Shinde, U. P., & Rotwein, P. S. (2009) · Biochemical Journal · doi:10.1042/bj20090978 · Cited by 74
B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation
Talay, O., Shen, C.-H., Chen, L., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813367106 · Cited by 72
McPherson, R. C., Konkel, J. E., Prendergast, C. T., Thomson, J. P., Ottaviano, R., Leech, M. D., Kay, O., Zandee, S., Sweenie, C. H., Wraith, D. C., et al. (2014) · eLife · doi:10.7554/elife.03416 · Cited by 70
Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection
Allie, S. R., Zhang, W., Fuse, S., & Usherwood, E. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003870 · Cited by 66
Ding, H., Wu, X., Wu, J., Yagita∥, H., He, Y., Zhang, J., Ren, J., & Gao, W. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.10.017 · Cited by 65
Rowe, J. H., Johanns, T. M., Ertelt, J. M., & Way, S. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7553 · Cited by 60
Pauken, K. E., Nelson, C. E., Martinov, T., Spanier, J. A., Heffernan, J. R., Sahli, N. L., Quarnstrom, C. F., Osum, K. C., Schenkel, J. M., Jenkins, M. K., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402262 · Cited by 52
Self-citationKean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 52
Floyd, T. L., Koehn, B. H., Kitchens, W. H., Robertson, J. M., Cheeseman, J. A., Stempora, L., Larsen, C. P., & Ford, M. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003015 · Cited by 33
Eberlein, J., Davenport, B., Nguyen, T. T., Victorino, F., Sparwasser, T. D., & Homann, D. (2011) · Journal of Virology · doi:10.1128/jvi.05949-11 · Cited by 30
van Noort, J. M., van Sechel, A. C., Boon, J., Boersma, W. J. A., Polman, C. H., & Lucas, C. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90234-p · Cited by 28
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
An aged immune system drives senescence and ageing of solid organs
Yousefzadeh, M. J., Flores, R. R., Zhu, Y., Schmiechen, Z. C., Brooks, R. W., Trussoni, C. E., Cui, Y., Angelini, L., Lee, K.-A., McGowan, S. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03547-7 · Cited by 972
Metadata
- Authors
- Sharpe, A. H., & Pauken, K. E.
- Venue
- Nature Reviews Immunology
- Published
- 2017-11-13
- Volume
- 18
- Issue
- 3
- Pages
- 153-167
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2761586559
- Cited by
- 1,971
- References
- 176
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.